|Bid||17.380 x 0|
|Ask||17.400 x 0|
|Day's Range||17.140 - 18.000|
|52 Week Range||17.140 - 29.000|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||10.80|
|Forward Dividend & Yield||0.46 (2.63%)|
|Ex-Dividend Date||Jul 31, 2023|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for 2196.HK
On August 29, 2023, Shanghai Fosun Pharmaceutical Co., Ltd.* (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first half of 2023. (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue of RMB21.395 billion; the net profit attributable to shareholders of the listed company was RMB1.777 billion, with a period-on-period growth of 15.74%.
Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun PharmaWALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that a New Drug Application (NDA) for tenapanor has been accepted for review by China’s Center for Drug Evaluation of the National Medical
From June 5th to 8th (Pacific Standard Time), the 2023 BIO International Convention ("BIO 2023") will be held in Boston, Massachusetts, USA. The BIO International Convention is the world's largest gathering of the biotechnology industry along with industry-leading investor and partnering meetings held around the world.